Are all licensed haemostatic agents for haemophilia therapy accessible to patients?-Reference-Cited by-同舟云学术

Are all licensed haemostatic agents for haemophilia therapy accessible to patients?

Published:2022-09-19 Issue:6 Volume:28 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Berger Karin¹²,Batorova Angelika³,Bohn Rhonda⁴,di Minno Matteo⁵,Mannucci Pier Mannuccio⁶,Kavakli Kaan⁷,Schramm Wolfgang⁸,Aledort Louis⁹,

Affiliation:

1. Institute for Medical Information Processing, Biometry, Epidemiology, IBE, Ludwig‐Maximilian University Munich Germany

2. Department of Hematology, Oncology Ludwig‐Maximilian University ‐ Hospital Munich Germany

3. Department of Haematology and Transfusion Medicine and National Haemophilia Centre University Hospital, Comenius University Bratislava Slovakia

4. Bohn Epidemiology Boston Massachusetts USA

5. Department of Hematology and Oncology, Unit of Internal Medicine and Haemostasis; and Department of Clinical Medicine and Surgery Federico II University Hospital Naples Italy

6. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan Italy

7. Department Hematology Bornova Ege University Children's Hospital, Izmir Turkey

8. Ludwig‐Maximilian‐University Rudolf‐Marx‐Foundation Munich Germany

9. Division of Hematology/Oncology Icahn School of Medicine, Mount Sinai New York New York USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14660

Reference9 articles.

1. Hemophilia therapy: the future has begun

2. Novel therapeutics for hemophilia and other bleeding disorders

3. Novel approaches to hemophilia therapy: successes and challenges

4. The economics of haemophilia prophylaxis: governmental and insurer perspectives. PROCEEDINGS OF THE SECOND INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) SYMPOSIUM